Mumbai based Fintech start-up, 5paisa Capital Limited strengthened its position in the discount broking segment as its active client base increased by 486 per cent YoY. The company now has an active client base of 83,328 against 14,217 a year ago.

The EU General Court thrashed the company's appeal against the European Commission’s decision to impose a penalty on Unichem in the perindopril patent case. The company is reviewing the judgement and might appeal before the European Court of Justice.

Market participants had expected SEBI to allow mutual funds to practice side-pocketing and it is now official granted. Read on to know more.

Following stocks are close to their 52-week low as at 12.34 p.m. on December 13, 2018.

The markets on December 13, 2018 opened gap up. BSE Sensex is trading at 35,949.89, up by 170.82 points and the Nifty is trading at 10,793.40, up by 55.80 points. 

Strides Pharma’s step-down wholly-owned subsidiary, Strides Pharma Globe Pte. Limited, Singapore, received USFDA approval for Lidocaine Ointment. The stocks of Strides gained 2 per cent in the morning trading session.

The company has received appointment date from the National Highways Authority of India (NHAI) for an EPC project worth Rs. 981 crore in Uttar Pradesh. 

Overall volumes in futures & options currently stand at 1.67 crore contracts with a turnover of Rs. 9,56,463.76 crore.

Overall volumes in futures & options currently stand at 1.67 crore contracts with a turnover of Rs. 9,56,463.76 crore.

It would be important for the Nifty to surpass its 200-day moving average and trade above this zone for extending its rally. Sustaining above the 200-day moving average will open up for upmove towards the levels of 10,840-10,890. Stocks in news: Lupin, Stride Pharma Science, Pricol, Sadbhav Engineering and Punjab & Sind Bank.